TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05016427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VT301
Description: VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VT301
Description: VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
Study: NCT01933282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESA chemotherapy
Description: Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESA
Description: Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
Study: NCT00928057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4mm x 32G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4mm x 32G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm x 31G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
Study: NCT01987128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural injection
Description: BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraneural injection
Description: BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK SonoPlex 22G needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAJUNK SonoPlex 22G needle.
Study: NCT01786746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally adapted cognitive behavioral therapy
Description: culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
Study: NCT05270382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.
Study: NCT00171145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 15 mg tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study: NCT05270382

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.
Study: NCT04515849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 100 micrograms
Description: Cotadutide 100 micrograms administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 300 micrograms
Description: Cotadutide 300 micrograms administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 600 micrograms
Description: Cotadutide 600 micrograms administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide 1.0 miligrams administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT02935855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study: NCT04100070

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Monitoring of the patients
Description: Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)
Study: NCT02935855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acenocumarole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acenocumarole
Study: NCT04129632

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IEPF Wellness Tool
Description: A daily 5 minute mindfulness exercise over 28 days
Study: NCT01607411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Fluoride Toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Fluoride Toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Fluoride Toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoride free toothpaste
Study: NCT03540368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administering placebo or sodium chloride 0,9% intravenously
Study: NCT04083911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF
Description: Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study: NCT02502877

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard
Description: The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).

Intervention type: DEVICE
Group type: OTHER
Intervention: SpotOn
Description: Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpotOn
Description: Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
Study: NCT02711644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Lifestyle Counselling
Description: Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Counselling
Description: Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Counselling
Description: Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
Study: NCT00991796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
Study: NCT04436419

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid (plus full hospitalization)
Description: Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)
Description: Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
Study: NCT00740896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking
Description: Active Comparator: Participants smoke 8 cigarettes in 4 hours.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Smoking
Description: Sham Comparator: Participants are not allowed to smoke for 4 hours.
Study: NCT01852799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD Followed by ASCT
Description: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
Study: NCT01456273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Medical Consultation
Description: Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Medical Consultation
Description: Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Encounter
Description: Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Encounter
Description: Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo.
Study: NCT00808431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
Study: NCT04426578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count.
Study: NCT03824067

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Early Infant Diagnosis
Description: HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Study: NCT00281944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT03556384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters
Study: NCT03824067

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Early Infant Diagnosis
Description: Conventional laboratory based EID testing
Study: NCT02547285

Intervention type: OTHER
Intervention: Shoes characteristics
Description: A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
Study: NCT01522729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: placebo \[NaCl\]
Study: NCT00218127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: LAAM Fixed Dose evaluation up to 48 mg 48 mg
Study: NCT01854931

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tai Ji Quan
Description: single aim intervention
Study: NCT01753739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
Study: NCT00371501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 80mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02021656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily without regard to food
Study: NCT04449471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen tablet
Description: For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.